Can this actually be done? I understand that a company can patent different ways of administering the patented molecule (e.g., liquid and pill) and slightly different forms of the molecule (I forget the proper terms and specifics, but Anavex has patented something like right-handed, left-handed, and mixed versions of A2-73) and uses to which the molecule can be put (e.g., for Alzheimer's and insomnia and to provide oxygen assist to prevent anoxic damage, such as at high altitudes) – but what's to keep another company from discovering and marketing a different molecule that similarly impacts the Sigma 1 pathways (similar perhaps to Cialis and Viagra, both of which "are PDE5 inhibitors that allow for increased blood flow to the penis") and perhaps treats some of the same indications? Are there any pharmaceutical companies that have managed to "own" a mode of action or particular cellular pathway?
News 
Market Data 
Discover 
